Abstract:Colorectal cancer (CRC) remains one of the most prevalent and fatal malignancies worldwide, consistently ranking among the top three in terms of incidence and mortality. Despite notable advancements in early detection and therapeutic interventions, survival outcomes for advanced-stage CRC are still dismal, largely due to issues such as drug resistance and metastasis. Recent research has increasingly implicated the JAK-STAT signaling pathway as a pivotal contributor to CRC pathogenesis. This evolutionarily conserved pathway plays a key role in transmitting extracellular signals to the nucleus, thereby modulating gene expression involved in numerous fundamental biological processes. In CRC, dysregulation of the JAK-STAT pathway is frequently observed and is strongly associated with tumor progression, including processes such as cellular proliferation, apoptosis, metastasis, immune evasion, and the sustenance of cancer stem cells. Given its integral role in CRC advancement, the JAK-STAT pathway has gained recognition as a viable therapeutic target. Extensive evidence from preclinical and clinical models supports the efficacy and safety of targeting components of the JAK-STAT pathway, presenting new therapeutic possibilities for patients with CRC, particularly in addressing drug resistance and enhancing treatment outcomes. This review offers a detailed exploration of the JAK-STAT pathway, focusing on its regulatory mechanisms in CRC-related malignancies. Moreover, it examines the association between JAK-STAT protein expression, clinical features, prognosis, and its therapeutic potential in CRC management.

JAK/STAT in leukemia: a clinical update

Advances in the Research of JAK2 Abnormalities in Heamatological Disorders

[Inhibitors of JAK2/STAT Signaling Pathway and Hematologic Malignancies-Review].

Molecular basis of JAK2 H608Y and H608N mutations in the pathology of acute myeloid leukemia

Deciphering JAK/STAT signaling pathway: A multifaceted approach to tumorigenesis, progression and therapeutic interventions

Recent Advances in Signaling Pathways and Kinase Inhibitors for Leukemia Chemotherapy

JAK2 inhibitors for the treatment of Philadelphia-negative myeloproliferative neoplasms: current status and future directions

The JAK/STAT signaling pathway: from bench to clinic

JAK/STAT Signal Transduction: Promising Attractive Targets for Immune, Inflammatory and Hematopoietic Diseases

Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer

Constitutive Activation of JAK/STAT Signaling Pathway in Leukemogenesis

New advances in the role of JAK2 V617F mutation in myeloproliferative neoplasms

Roles of Germline JAK2 Activation Mutation JAK2 V625F in the Pathology of Myeloproliferative Neoplasms

[Progress of Study on JAK2V617F Mutation in Myeloproliferative Neoplasm].

Janus Kinase Signaling: Oncogenic Criminal of Lymphoid Cancers

Janus kinase-signal transducer and activator of transcription signaling pathways in non-small cell lung cancer: research progress

JAK/STAT pathway: Extracellular signals, diseases, immunity, and therapeutic regimens

Recent Progress in the Studies on Structure and Function of JAK2

The Associations of Janus Kinase-2 (jak2) A830g Polymorphism and the Treatment Outcomes in Patients with Acute Myeloid Leukemia

Dual-target Janus Kinase (JAK) Inhibitors: Comprehensive Review on the JAK-based Strategies for Treating Solid or Hematological Malignancies and Immune-Related Diseases.

Targeting the JAK-STAT pathway in colorectal cancer: mechanisms, clinical implications, and therapeutic potential